DIPIVEFRIN AND ECHOTHIOPHATE - CONTRAINDICATIONS TO COMBINED USE

被引:9
作者
ABRAMOVSKY, I
MINDEL, JS
机构
[1] VET ADM HOSP,BRONX,NY 10468
[2] CUNY MT SINAI SCH MED,DEPT OPHTHALMOL,NEW YORK,NY 10029
[3] CUNY MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029
关键词
D O I
10.1001/archopht.1979.01020020385024
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
A study was undertaken to determine whether the antiesterase activity of echothiophate iodide would prevent the conversion of dipivefrin to epinephrine. Dipivefrin was administered singly and in combination with echothiophate to 24 adult rabbits. Administration of dipivefrin lowered the intraocular pressure (IOP) 8 ± 1 mm Hg (P <.001). When echothiophate was given before and concomitant with dipivefrin, there was no further decrease in IOP compared with that produced by echothiophate alone (5 ± 1 mm Hg). Addition of epinephrine to eyes receiving dipivefrin plus echothiophate resulted in a significant additional decrease in IOP of 4 ± 1 mm Hg (P <.001). When echothiophate was given after dipivefrin had lowered the IOP and both drugs were continued, the IOP rose to baseline levels. These results fit the theory that the esterase converting dipivefrin to epinephrine is inactivated by cholinesterase inhibitors. The clinical use of cholinesterase inhibitors and dipivefrin may be contraindicated. © 1979, American Medical Association. All rights reserved.
引用
收藏
页码:1937 / 1940
页数:4
相关论文
共 9 条
[1]   LENS OPACITIES IN GLAUCOMA PATIENTS ON PHOSPHOLINE IODIDE THERAPY [J].
DEROETTH, A .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1966, 62 (04) :619-&
[2]   PRODRUG APPROACHES TO ENHANCEMENT OF PHYSICOCHEMICAL PROPERTIES OF DRUGS .4. NOVEL EPINEPHRINE PRODRUG [J].
HUSSAIN, A ;
TRUELOVE, JE .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1976, 65 (10) :1510-1512
[3]   EFFECTS OF DIPIVALYL EPINEPHRINE ON EYE [J].
KABACK, MB ;
PODOS, SM ;
HARBIN, TS ;
MANDELL, A ;
BECKER, B .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1976, 81 (06) :768-772
[4]  
KOELLE GB, 1975, PHARM BASIS THERAPEU, P455
[5]  
MANDELL AI, 1978, OPHTHALMOLOGY, V85, P268
[6]  
MANDELL AI, 1977, S OCULAR THERAPY, V10, P109
[7]  
MCCLURE DA, 1975, PRODRUGS NOVEL DRUG, P224
[8]  
WEI C, 1978, INVEST OPHTH VIS SCI, V17, P315
[9]  
YABLONSKI ME, 1977, ARCH OPHTHALMOL-CHIC, V95, P2157